A Study of Pembrolizumab and Olaparib in People With Endometrial Cancer or Endometrial Carcinosarcoma
Status:
Not yet recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to find out whether the combination of pembrolizumab and
olaparib is an effective treatment for people with persistent or recurrent endometrial cancer
or endometrial carcinosarcoma. The researchers will also look at the safety of the drug
combination and whether it causes few or mild side effects in participants.